Jing Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4146374/publications.pdf

Version: 2024-02-01

135	12,729	26630 56	24982 109
papers	citations	h-index	g-index

136	136	136	13554
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Aggregated Î±â€synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB Journal, 2005, 19, 533-542.	0.5	1,065
2	DJ-1 and Î±-synuclein in human cerebrospinal fluid as biomarkers of Parkinsonâ€™s disease. Brain, 2010, 133, 713-726.	7.6	575
3	Parkinson's Disease Is Associated with Oxidative Damage to Cytoplasmic DNA and RNA in Substantia Nigra Neurons. American Journal of Pathology, 1999, 154, 1423-1429.	3.8	570
4	Plasma exosomal Î±-synuclein is likely CNS-derived and increased in Parkinsonâ€™s disease. Acta Neuropathologica, 2014, 128, 639-650.	7.7	504
5	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology, 2011, 69, 570-580.	5.3	371
6	Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. Journal of Alzheimer's Disease, 2006, 9, 293-348.	2.6	362
7	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.8	354
8	Mass Spectrometry Based Targeted Protein Quantification: Methods and Applications. Journal of Proteome Research, 2009, 8, 787-797.	3.7	349
9	CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases. American Journal of Clinical Pathology, 2008, 129, 526-529.	0.7	248
10	Phosphorylated Î±-Synuclein in Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 121ra20.	12.4	223
11	Proteomic Identification of a Stress Protein, Mortalin/mthsp70/GRP75. Molecular and Cellular Proteomics, 2006, 5, 1193-1204.	3.8	220
12	Alphaâ€Synuclein as a Biomarker for Parkinson's Disease. Brain Pathology, 2016, 26, 410-418.	4.1	217
13	Manganese ethyleneâ€bisâ€dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. Journal of Neurochemistry, 2003, 84, 336-346.	3.9	201
14	Salivary Î±-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain, 2011, 134, e178-e178.	7.6	196
15	Proteomic Identification of Novel Proteins in Cortical Lewy Bodies. Brain Pathology, 2007, 17, 139-145.	4.1	194
16	Transmission of Î±-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinsonâ€™s disease?. Acta Neuropathologica Communications, 2017, 5, 71.	5.2	188
17	Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neuroscience Letters, 2010, 480, 78-82.	2.1	184
18	The Transport Mechanism of Extracellular Vesicles at the Blood-Brain Barrier. Current Pharmaceutical Design, 2018, 23, 6206-6214.	1.9	177

#	Article	IF	Citations
19	Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergentâ€insoluble paired helical filament tau binding protein. FASEB Journal, 2005, 19, 1-12.	0.5	172
20	Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiology of Aging, 2005, 26, 207-227.	3.1	162
21	CSF Aî²₄₂ and tau in Parkinson's disease with cognitive impairment. Movement Disorders, 2010, 25, 2682-2685.	3.9	162
22	Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. Journal of Alzheimer's Disease, 2005, 7, 125-133.	2.6	160
23	SNCA Variant Associated With Parkinson Disease and Plasma Î±-Synuclein Level. Archives of Neurology, 2010, 67, 1350-6.	4.5	157
24	CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1125-1131.	0.8	154
25	Identification of Novel Proteins Associated with Both Î±-Synuclein and DJ-1. Molecular and Cellular Proteomics, 2007, 6, 845-859.	3.8	153
26	Salivary Tau Species are Potential Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 299-305.	2.6	153
27	Analysis of Î±-Synuclein-associated Proteins by Quantitative Proteomics. Journal of Biological Chemistry, 2004, 279, 39155-39164.	3.4	149
28	Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia, 2007, 55, 1178-1188.	4.9	147
29	Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy. Journal of Alzheimer's Disease, 2016, 51, 1099-1109.	2.6	146
30	Alpha synuclein is transported into and out of the brain by the bloodâ€“brain barrier. Peptides, 2014, 62, 197-202.	2.4	138
31	Rab11a and HSP90 Regulate Recycling of Extracellular Î±-Synuclein. Journal of Neuroscience, 2009, 29, 1480-1485.	3.6	128
32	Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Molecular Brain Research, 2005, 134, 119-138.	2.3	126
33	Cerebrospinal Fluid Î±-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort. American Journal of Pathology, 2014, 184, 966-975.	3.8	126
34	Î±-Synuclein, a chemoattractant, directs microglial migration via H₂O₂-dependent Lyn phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1926-35.	7.1	123
35	New windows into the brain: Central nervous system-derived extracellular vesicles in blood. Progress in Neurobiology, 2019, 175, 96-106.	5.7	121
36	A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics, 2007, 7, 469-473.	2.2	111

#	Article	IF	Citations
37	Biomarker discovery in neurodegenerative diseases: A proteomic approach. Neurobiology of Disease, 2009, 35, 157-164.	4.4	102
38	Glycoproteomics in neurodegenerative diseases. Mass Spectrometry Reviews, 2010, 29, 79-125.	5.4	99
39	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. American Journal of Pathology, 2011, 178, 1509-1516.	3.8	97
40	P2X7 receptor is critical in Î±-synucleinâ€“mediated microglial NADPH oxidase activation. Neurobiology of Aging, 2015, 36, 2304-2318.	3.1	94
41	DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Scientific Reports, 2012, 2, 954.	3.3	90
42	CSF Î±-synuclein improves diagnostic and prognostic performance of CSF tau and AÎ² in Alzheimerâ€™s disease. Acta Neuropathologica, 2013, 126, 683-697.	7.7	90
43	Catalysis of catechol oxidation by metal-dithiocarbamate complexes in pesticides. Free Radical Biology and Medicine, 2002, 33, 1714-1723.	2.9	87
44	Oligomeric Î±-synuclein inhibits tubulin polymerization. Biochemical and Biophysical Research Communications, 2007, 356, 548-553.	2.1	86
45	CSF tau and tau/AÎ²42 predict cognitive decline in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 271-276.	2.2	81
46	Mortalin: A Protein Associated With Progression of Parkinson Disease?. Journal of Neuropathology and Experimental Neurology, 2008, 67, 117-124.	1.7	77
47	Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathologica, 2013, 126, 671-682.	7.7	76
48	Identification of Glutathione S-Transferase Pi as a Protein Involved in Parkinson Disease Progression. American Journal of Pathology, 2009, 175, 54-65.	3.8	75
49	Î±-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2013, 36, 679-688.	2.6	74
50	Phosphorylated Î±-synuclein in Parkinsonâ€™s disease: correlation depends on disease severity. Acta Neuropathologica Communications, 2015, 3, 7.	5.2	74
51	Microglial Activation Induced by Neurodegeneration. Molecular and Cellular Proteomics, 2005, 4, 1471-1479.	3.8	71
52	Using â€˜omicsâ€™ to define pathogenesis and biomarkers of Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 925-942.	2.8	71
53	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiology of Disease, 2015, 80, 29-41.	4.4	71
54	Application of Targeted Quantitative Proteomics Analysis in Human Cerebrospinal Fluid Using a Liquid Chromatography Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Tandem Mass Spectrometer (LC MALDI TOF/TOF) Platform. Journal of Proteome Research, 2008, 7, 720-730.	3.7	67

#	Article	IF	Citations
55	Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. Brain, 2020, 143, 1780-1797.	7.6	66
56	Erythrocytic Î±-Synuclein as a potential biomarker for Parkinsonâ€™s disease. Translational Neurodegeneration, 2019, 8, 15.	8.0	65
57	Identification of Proteins Involved in Microglial Endocytosis of Î±-Synuclein. Journal of Proteome Research, 2007, 6, 3614-3627.	3.7	64
58	Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2011, 17, 61-64.	2.2	64
59	Identification of Synaptosomal Proteins Binding to Monomeric and Oligomeric Î±-Synuclein. PLoS ONE, 2015, 10, e0116473.	2.5	63
60	Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia, 2006, 53, 567-582.	4.9	56
61	Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. Journal of Alzheimer's Disease, 2006, 8, 377-386.	2.6	55
62	Salivary total Î±-synuclein, oligomeric Î±-synuclein and SNCA variants in Parkinsonâ€™s disease patients. Scientific Reports, 2016, 6, 28143.	3.3	55
63	Premotor biomarkers for Parkinson's disease - a promising direction of research. Translational Neurodegeneration, 2012, 1, 11.	8.0	54
64	A user's guide for Î±â€synuclein biomarker studies in biological fluids: Perianalytical considerations. Movement Disorders, 2017, 32, 1117-1130.	3.9	54
65	Biomarkers of Parkinson's disease: current status and future perspectives. Drug Discovery Today, 2013, 18, 155-162.	6.4	52
66	Secondary Excitotoxicity Contributes to Dopamine-Induced Apoptosis of Dopaminergic Neuronal Cultures. Biochemical and Biophysical Research Communications, 1998, 248, 812-816.	2.1	51
67	Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation*. Molecular and Cellular Proteomics, 2015, 14, 544-555.	3.8	51
68	Tau Proteins Cross the Blood-Brain Barrier. Journal of Alzheimer's Disease, 2016, 55, 411-419.	2.6	50
69	Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomarkers in Medicine, 2017, 11, 451-473.	1.4	49
70	Proteomics of human cerebrospinal fluid â€“ the good, the bad, and the ugly. Proteomics - Clinical Applications, 2007, 1, 805-819.	1.6	48
71	Proteomic determination of widespread detergent insolubility, including AÎ² but not tau, early in the pathogenesis of Alzheimer's disease. FASEB Journal, 2005, 19, 1923-1925.	0.5	46
72	Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cells. BMC Neuroscience, 2007, 8, 67.	1.9	45

#	Article	IF	Citations
73	Proteomics Identification of Proteins in Human Cortex Using Multidimensional Separations and MALDI Tandem Mass Spectrometer. Molecular and Cellular Proteomics, 2007, 6, 1818-1823.	3.8	44
74	Antibodyâ€based methods for the measurement of Î±â€synuclein concentration in human cerebrospinal fluid â€“ method comparison and round robin study. Journal of Neurochemistry, 2019, 149, 126-138.	3.9	44
75	Astrocytic <scp>VEGFA</scp>: An essential mediator in bloodâ€“brainâ€barrier disruption in Parkinson's disease. Glia, 2022, 70, 337-353.	4.9	44
76	Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease. Movement Disorders, 2015, 30, 1893-1900.	3.9	42
77	Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression. Scientific Reports, 2018, 8, 2098.	3.3	42
78	Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2016, 6, 109-117.	2.8	40
79	A role for a novel protein, nucleolin, in Parkinson's disease. Neuroscience Letters, 2009, 459, 11-15.	2.1	39
80	Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults. Alzheimer's Research and Therapy, 2017, 9, 48.	6.2	38
81	Biochemical premotor biomarkers for Parkinson's disease. Movement Disorders, 2012, 27, 644-650.	3.9	37
82	Coniferaldehyde attenuates Alzheimer's pathology via activation of Nrf2 and its targets. Theranostics, 2020, 10, 179-200.	10.0	37
83	Proteomic Analysis of Saliva from Patients with Oral Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 1048-1055.	2.0	35
84	Predominant Release of Lysosomal Enzymes by Newborn Rat Microglia After LPS Treatment Revealed by Proteomic Studies. Journal of Proteome Research, 2008, 7, 2033-2049.	3.7	34
85	DJ-1 and Î±SYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiology of Aging, 2012, 33, 836.e5-836.e7.	3.1	34
86	Cerebrospinal fluid Î±â€synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1052-1062.	0.8	34
87	Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. Journal of Neurochemistry, 2019, 151, 397-416.	3.9	34
88	Identification of proteins in human substantia nigra. Proteomics - Clinical Applications, 2008, 2, 776-782.	1.6	33
89	Biomarkers for Cognitive Impairment in Parkinson Disease. Brain Pathology, 2010, 20, 660-671.	4.1	33
90	Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2015, 74, 672-687.	1.7	33

#	Article	IF	Citations
91	Proteomics of Human Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2008, 67, 923-932.	1.7	31
92	Targeted Discovery and Validation of Plasma Biomarkers of Parkinsonâ€™s Disease. Journal of Proteome Research, 2014, 13, 4535-4545.	3.7	30
93	Cheek cellâ€“derived Î±-synuclein and DJ-1 do not differentiate Parkinson's disease from control. Neurobiology of Aging, 2014, 35, 418-420.	3.1	30
94	Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid Î² 1â€“42 in CSF for the Diagnosis of Alzheimerâ€™s Disease. Journal of Proteome Research, 2017, 16, 1228-1238.	3.7	30
95	A Longitudinal Study of Total and Phosphorylated Î±-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimerâ€™s Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 61, 1541-1553.	2.6	29
96	Plasma Î±-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study. Neurobiology of Disease, 2018, 116, 53-59.	4.4	29
97	Enhancement of Dopaminergic Neurotoxicity by the Mercapturate of Dopamine. Journal of Neurochemistry, 2000, 74, 970-978.	3.9	28
98	Characterization of Proteome of Human Cerebrospinal Fluid. International Review of Neurobiology, 2006, 73, 29-98.	2.0	28
99	Diagnostic Values of Cerebrospinal Fluid T-Tau and AÎ²42 using Meso Scale Discovery Assays for Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 709-719.	2.6	28
100	Cerebrospinal Fluid Î±-Synuclein and Lewy Body-Like Symptoms in Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1007-1016.	2.6	27
101	Astrocytic Dynamin-Like Protein 1 Regulates Neuronal Protection against Excitotoxicity in Parkinson Disease. American Journal of Pathology, 2015, 185, 536-549.	3.8	27
102	Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. Alzheimer's Research and Therapy, 2014, 6, 36.	6.2	26
103	Erythrocytic Î±-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinsonâ€™s disease pathogenesis. Acta Neuropathologica Communications, 2020, 8, 102.	5.2	26
104	Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 779-787.	2.3	25
105	Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinsonâ€™s disease. Brain, 2015, 138, 2672-2686.	7.6	24
106	Immunoregulation of microglial polarization: an unrecognized physiological function of Î±-synuclein. Journal of Neuroinflammation, 2020, 17, 272.	7.2	22
107	Identification of a specific Î±-synuclein peptide (Î±-Syn 29-40) capable of eliciting microglial superoxide production to damage dopaminergic neurons. Journal of Neuroinflammation, 2016, 13, 158.	7.2	21
108	Blood extracellular vesicles carrying synaptic functionâ€•and brainâ€•related proteins as potential biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 909-923.	0.8	21

#	Article	IF	Citations
109	Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease. Proteomics - Clinical Applications, 2008, 2, 1484-1497.	1.6	20
110	Parkinson's Disease Derived Exosomes Aggravate Neuropathology in <scp>SNCA</scp>*<scp>A53T</scp> Mice. Annals of Neurology, 2022, 92, 230-245.	5.3	19
111	Time-Resolved Proteomic Visualization of Dendrimer Cellular Entry and Trafficking. Journal of the American Chemical Society, 2015, 137, 12772-12775.	13.7	18
112	Mortalin is Expressed by Astrocytes and Decreased in the Midbrain of Parkinson's Disease Patients. Brain Pathology, 2016, 26, 75-81.	4.1	18
113	Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying Î±-Synucleinâ€“Containing Extracellular Vesicles. Neurology, 2021, 96, e2332-e2345.	1.1	18
114	Î±-Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinsonâ€™s disease. Journal of Neuroinflammation, 2022, 19, 53.	7.2	17
115	Effects of Baseline CSF Î±-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e85443.	2.5	16
116	CSF Î±-synuclein, tau, and amyloid Î² in Parkinson's disease. Lancet Neurology, The, 2011, 10, 681.	10.2	15
117	Increased CSF E-Selectin in Clinical Alzheimerâ€™s Disease without Altered CSF AÎ² 42 and Tau. Journal of Alzheimer's Disease, 2015, 47, 883-887.	2.6	15
118	Biomarkers for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2007, 7, 1021-1028.	2.8	14
119	Cerebrospinal fluid AÎ²₄₂ levels and APP processing pathway genes in Parkinson's disease. Movement Disorders, 2015, 30, 936-944.	3.9	14
120	Fine Particulate Matter Exposure and Cerebrospinal Fluid Markers of Vascular Injury. Journal of Alzheimer's Disease, 2019, 71, 1015-1025.	2.6	14
121	Biofluid Biomarkers of Mild Traumatic Brain Injury. JAMA Neurology, 2015, 72, 1103.	9.0	13
122	Extracellular microvesicles-derived from microglia treated with unaggregated Î±-synuclein attenuate mitochondrial fission and toxicity-induced by Parkinsonian toxin MPP+. Biochemical and Biophysical Research Communications, 2019, 517, 642-647.	2.1	13
123	Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 263-276.	2.6	13
124	Identification of ciliary neurotrophic factor receptor Î± as a mediator of neurotoxicity induced by Î±â€synuclein. Proteomics, 2010, 10, 2138-2150.	2.2	12
125	Quantitative Proteomic Analysis of Oligodendrogliomas With and Without 1p/19q Deletion. Journal of Proteome Research, 2010, 9, 2610-2618.	3.7	12
126	Combining clinical and biofluid markers for early Parkinson's disease detection. Annals of Clinical and Translational Neurology, 2018, 5, 109-114.	3.7	10

#	Article	IF	Citations
127	Applying bioinformatics to proteomics: Is machine learning the answer to biomarker discovery for PD and MSA?. Movement Disorders, 2012, 27, 1595-1597.	3.9	9
128	An alphaâ€synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression. Proteomics - Clinical Applications, 2017, 11, 1700045.	1.6	9
129	Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 37.	5.2	8
130	Blood Î±-synuclein in agricultural pesticide handlers in central Washington State. Environmental Research, 2015, 136, 75-81.	7.5	6
131	Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker. Clinical Cancer Research, 2020, 26, 193-205.	7.0	6
132	An Update on CSF Biomarkers of Parkinsonâ€™s Disease. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 161-184.	0.6	5
133	Biomarkers of Parkinsonâ€™s Disease. Biomarkers in Disease, 2015, , 1009-1030.	0.1	0
134	Mortalin in Neurological Diseases. , 2012, , 139-158.		0
135	Biomarkers of Parkinsonâ€™s Disease. , 2014, , 1-18.		0